# A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD

> **NCT04714359** · PHASE3 · COMPLETED · sponsor: **Resilient Pharmaceuticals** · enrollment: 87 (actual)

## Conditions studied

- PTSD

## Interventions

- **DRUG:** Midomafetamine HCl

## Key facts

- **NCT ID:** NCT04714359
- **Lead sponsor:** Resilient Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-08
- **Primary completion:** 2023-11-01
- **Final completion:** 2023-11-06
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2025-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04714359

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04714359, "A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04714359. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*